ofirmevEdelman and Kekst and Company are advising Irish pharmaceutical maker Mallinckrodt's $1.3B acquisition of Cadence Pharmaceuticals.

Kekst vice chair Jeff Taufield supports Mallinckrodt's U.S. in-house team, which is based in St. Louis and led by SVP of communications and public affairs Meredith Fischer and VP of IR John Moten.

Edelman guides PR for San Diego-based Cadence, a biopharma company that makes drugs used in a hospital setting.

Cadence's OFIRMEV acetaminophen injection chalked up net revenues of $110.5M in 2013, more than doubling the prior year's sales.

The $14-per-share tender offer announced Feb. 11 is a 32% premium on Cadence shares.

The deal is expected to close next month.